Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- Chapters
- descriptions off, selected
- subtitles settings, opens subtitles settings dialog
- subtitles off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
Dr David Stamler – CEO – Alterity Therapeutics Limited (ASX:ATH) is developing first-in-class therapies to treat neurodegenerative disease. The company's lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
Post Views: 547